Amyloid P component. A critical review

Amyloid

Volumn 4, Issue 4, 1997, Pages 274-295

  Pepys, M B ^a   Booth, D R ^a   Hutchinson, W L ^a   Gallimore, J R ^a   Collins, P M ^b   Hohenester, E ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Amyloid; Amyloid P component (AP); Amyloidosis; Crystal structure; Ligand binding; Serum amyloid P component (SAP)

Indexed keywords

EID: 0000186474     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129709003838     Document Type: Review

References (228)

1. Cathcart ES, Comerford FR and Cohen AS (1965). Immunologic studies on a protein extracted from human secondary amyloid. N Engl J Med 273,143-146
2. Cathcart ES, Shirahama T and Cohen AS (1967). Isolation and identification of a plasma component of amyloid. Biochim Biophys Acta 147,392-393
3. Cathcart ES, Wollheim FA and Cohen AS (1967). Plasma protein constituents of amyloid fibrils. J Immunol 99, 376-385
4. Bladen HA, Nylen MU and Glenner GG (1966). The ultrastructure of human amyloid as revealed by the negative staining technique. J Ultrastruct Res 14, 449-459
5. Cohen AS and Calkins E (1959). Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183, 1202-1203
6. Glenner GG (1980). Amyloid deposits and amyloidosis - the β-fibrilloses. I. N Engl J Med 302, 1283-1292
7. Glenner GG (1980). Amyloid deposits and amyloidosis - the β-fibrilloses. II. N Engl J Med 302, 1333-1343
8. Pepys MB (1994). Amyloidosis. In Frank MM, Austen KF, Claman HN and Unanue ER (eds). Samter's Immunologic Diseases, Fifth Ed., pp. 637-655. (Boston: Little, Brown and Company)
9. 1-glykoproteins (CM-protein III). Hoppe-Seyler's Z Physiol Chem 353, 1841-1849
10. Binette JP and Calkins E (1973). The purification of the P-component. Arthritis Rheum 16, 536
11. Binette P, Binette M and Calkins E (1974). The isolation and identification of the P-component of normal human plasma proteins. Biochem J 143, 253-254
12. Assimeh SN and Painter RH (1975). The identification of a previously unrecognized subcomponent of the first component of complement. J Immunol 115, 482-487
13. Assimeh SN and Painter RH (1975). The macromolecular structure of the first component of complement. J Immunol 115, 488-494
14. Painter RH, Pinteric L, Hoffman T, Kells DIC and Katz A (1976). Ultrastructure and chemistry of Clt subcomponent of Cl: similarities to amyloid P component. J Immunol 116, 1745
15. Pepys MB, Dash AC, Munn EA, Feinstein A, Skinner M, Cohen AS, Gewurz H, Osmand AP and Painter RH (1977). Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet i, 1029-1031
16. Painter RH (1977). Evidence that Clt (amyloid P component) is not a subcomponent of the first component of complement (Cl). J Immunol 119, 2203-2205
17. Ziccardi RJ and Cooper NR (1977). The subunit composition and sedimentation properties of human Cl. J Immunol 118, 2047-2052
18. Cooper NR and Ziccardi RJ (1979). Amyloid P-component (Clt) and complement: lack of physical or functional relationship. Mol Immunol 16, 821-827
19. Ying S-C, Gewurz AT, Jiang H and Gewurz H (1993). Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of Clq. J Immunol 150, 169-176
20. Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T and Shelton E (1977). Characterisation of C-reactive protein and the complement subcomponent Clt as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 74, 739-743
21. Pepys MB and Baltz ML (1983). Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34, 141-212
22. Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB and Wood SP (1994). Structure of pentameric human serum amyloid P component. Nature 367, 338-345
23. Srinivasan N, White HE, Emsley J, Wood SP, Pepys MB and Blundell TL (1994). Comparative analyses of pentraxins: implications for protomer assembly and ligand binding. Structure 2, 1017-1027
24. Pepys MB, Dash AC, Fletcher TC, Richardson N, Munn EA and Feinstein A (1978). Analogues in other mammals and in fish of human plasma proteins C-reactive protein and amyloid P component. Nature 273, 168-170
25. Baltz ML, de Beer FC, Feinstein A, Munn EA, Milstein CP, Fletcher TC, March JF, Taylor J, Bruton C, Clamp JR, Davies AJS and Pepys MB (1982). Phylogenetic aspects of C-reactive protein and related proteins. Ann NY Acad Sci 389, 49-75
26. Lin L and Liu T-Y (1993). Isolation and characterization of C-reactive protein (CRP) cDNA and genomic DNA from Xenopus laevis. J Biol Chem 268, 6809-6815
27. Tennent GA, Butler PJG, Hutton T, Woolfit AR, Harvey DJ, Rademacher TW and Pepys MB (1993). Molecular characterization of Limulus polyphemus C-reactive protein. I. Subunit composition. Eur J Biochem 214, 91-97
28. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M, Della Valle G, Dejana E, Mantovani A and Introna M (1992). Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267, 22190-22197
29. Lee GW, Lee TH and Vilcek J (1993). TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 150, 1804-1812
30. Schlimgen AK, Helms JA, Vogel H and Perin MS (1995). Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system. Neuron 14, 519-526
31. Dodds D, Schlimgen AK, Lu S-Y and Perin MS (1995). Novel reticular calcium binding protein is purified on taipoxin columns. J Neurochem 64, 2339-2344
32. Tsui CC, Copeland NG, Gilbert DJ, Jenkins NA, Barnes C and Worley PF (1996). Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. J Neurosci 16, 2463-2478
33. Reid MS and Blobel CP (1994). Apexin, an acrosomal pentaxin. J Biol Chem 269, 32615-32620
34. Noland TD, Friday BB, Maulit MT and Gerton GL (1994). The sperm acrosomal matrix contains a novel member of the pentraxin family of calcium-dependent binding proteins. J Biol Chem 269, 32607-32614
35. Seery LT, Schoenberg DR, Barbaux S, Sharp PM and Whitehead AS (1993). Identification of a novel member of the pentraxin family in Xenopus laevis. Proc R Soc Lond B 253, 263-270
36. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, Hutton T and Dwek RA (1994). Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 91, 5602-5606
37. 2+-binding region of human serum amyloid P component and other pentraxins. Protein Sc 1, 700-709
38. Mantzouranis EC, Dowton SB, Whitehead AS, Edge MD, Bruns GAP and Colten HR (1985). Human serum amyloid P component. cDNA isolation, complete sequence of pre-serum amyloid P component, and localization of the gene to chromosome 1. J Biol Chem 260, 7752-7756
39. Kubak BM, Gewurz H and Potempa LA (1988). Identification of multiple forms of the P component of amyloid isolated from human serum. Int Arch Allergy Appl Immunol 87, 194-203
40. Sørensen IJ, Andersen O, Holm Nielsen E and Svehag S-E (1995). Multiple isoforms of the human pentraxin serum amyloid P component. Int Arch Allergy Immunol 106, 25-31
41. Prelli F, Pras M and Frangione B (1985). The primary structure of human tissue amyloid P component from a patient with primary idiopathic amyloidosis. J Biol Chem 260, 12895-12898
42. Ohnishi S, Maeda S, Shimada K and Arao T (1986). Isolation and characterization of the complete complementary and genomic DNA sequences of human serum amyloid P component. J Biochem 100, 849-858
43. Srinivasan N, Rufino SD, Pepys MB, Wood SP and Blundell TL (1996). A superfamily of proteins with the lectin fold. Chemtracts-Biochem Mol Biol 6, 149-164
44. Thompson AR and Enfield DL (1978). Human plasma P-component: isolation and characterization. Biochemistry 17, 4304-4311
45. 2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J Biol Chem 262, 1456-1460
46. Kubak BM, Potempa LA, Anderson B, Mahklouf S, Venegas M, Gewurz H and Gewurz AT (1988). Evidence that serum amyloid P component binds to mannose-terminated sequences of polysaccharides and glycoproteins. Mol Immunol 25, 851-858
47. Hamazaki H (1986). Purification and characterization of a human lectin specific for penultimate galactose residues. J Biol Chem 261, 5455-5459
48. Hind CRK, Collins PM, Renn D, Cook RB, Caspi D, Baltz ML and Pepys MB (1984). Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. J Exp Med 159, 1058-1069
49. Pontet M, Engler R and Jayle MF (1978). One step preparation of both human C-reactive protein and Clt. Fed Eur Biol Soc Lett 88, 172-178
50. Hawkins PN, Tennent GA, Woo P and Pepys MB (1991). Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol 84, 308-316
51. Schwalbe RA, Dahlbäck B, Coe JE and Nelsestuen GL (1992). Pentraxin family of proteins interact specifically with phosphocholine and/or phosphorylethanolamine. Biochemistry 31, 4907-4915
52. Pepys MB and Butler PJG (1987). Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun 148, 308-313
53. Butler PJG, Tennent GA and Pepys MB (1990). Pentraxin-chromatin interactions. Serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med 172, 13-18
54. Pepys MB, Booth SE, Tennent GA, Butler PJG and Williams DG (1994). Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 97, 152-157
55. Breathnach SM, Kofler H, Sepp N, Ashworth J, Woodrow D, Pepys MB and Hintner H (1989). Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. J Exp Med 170, 1433-1438
56. Du Clos TW, Mold C and Stump RF (1990). Identification of a polypeptide sequence that mediates nuclear localization of the acute phase protein C-reactive protein. J Immunol 145, 3869-3875
57. Pepys MB, Baltz M, de Beer FC, Dyck RF, Holford S, Breathnach SM, Black MM, Tribe CRF, Evans DJ and Feinstein A (1982). Biology of serum amyloid P component. Ann NY Acad Sci 389, 286-297
58. Pepys MB (1986). Amyloid P component: structure and properties. In Marrink J and van Rijswijk MH (eds). Amyloidosis, pp. 43-50. (Dordrecht: Martinus Nijhoff)
59. Pepys MB (1988). Amyloidosis. In Samter M, Talmage DW, Frank MM, Austen KF and Claman HN (eds). Immunological Diseases, 4th Ed., Vol. 1, pp. 631-674. (Boston: Little Brown & Co)
60. Skinner M and Cohen AS (1988). Amyloid P component. Methods Enzymol 163, 523-536
61. Gewurz H, Zhang XH and Lint TF (1995). Structure and function of the pentraxins. Curr Opin Immunol 7, 54-64
62. Hohenester E, Hutchinson WL, Pepys MB and Wood SP (1997). Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. J Mol Biol 269, 570-578
63. Rini JM (1995). Lectin structure. Ann Rev Biophys Biomol Struct 24, 551-577
64. McKinnon AC (1991). PhD Thesis. Sugar pyruvate acetals: their chemical synthesis and affinity for serum amyloid P component. Department of Chemistry, University of London, London
65. Hawkins PN, Myers MJ, Lavender JP and Pepys MB (1988). Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet i, 1413-1418
66. 123I-labeled serum amyloid P component. N Engl J Med 323, 508-513
67. Hawkins PN, Wootton R and Pepys MB (1990). Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 86, 1862-1869
68. Hawkins PN and Pepys MB (1995). Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med 22, 595-599
69. Pepys MB, Dyck RF, de Beer FC, Skinner M and Cohen AS (1979). Binding of serum amyloid P component (SAP) by amyloid fibrils. Clin Exp Immunol 38, 284-293
70. Nelson SR, Lyon M, Gallagher JT, Johnson EA and Pepys MB (1991). Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem J 215, 67-73
71. 2+ and amyloid P-component. Clin Exp Immunol 94, 189-195
72. Tennent GA, Lovat LB and Pepys MB (1995). Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci USA 92, 4299-4303
73. Lovat LB (1997). PhD Thesis. Molecular, therapeutic and clinical aspects of amyloidosis. Department of Medicine, University of London, London
74. Sørensen IJ, Andersen O, Holm Nielsen E and Svehag S-E (1995). Native human serum amyloid P component is a single pentamer. Scand J Immunol 41, 263-267
75. Ashton AW, Gallimore JR, Hutchinson WL, Butler PJG, Pepys MB and Perkins SJ (1997). Pentameric and decameric structures in solution of the serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol 272, 408-422
76. Ying S-C, Gupta K, Gewurz AT and Gewurz H (1993). Expression of human serum amyloid P component in COS-1 cells. Clin Res 41, 671A
77. Wood SP, Oliva G, O'Hara BP, White H, Blundell TL, Perkins SJ, Sardharwalla I and Pepys MB (1988). A pentameric form of human serum amyloid P component: crystallization, X-ray diffraction and neutron scattering studies. J Mol Biol 202, 169-173
78. Baltz ML, de Beer FC, Feinstein A and Pepys MB (1982). Calcium-dependent aggregation of human serum amyloid P component. Biochim Biophys Acta 701, 229-236
79. de Beer FC, Baltz M, Holford S, Feinstein A and Pepys MB (1981). Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. J Exp Med 154, 1134-1149
80. de Beer FC and Pepys MB (1982). Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods 50, 17-31
81. Coe JE and Ross MJ (1985). Hamster female protein, a sex-limited pentraxin, is a constituent of Syrian hamster amyloid. J Clin Invest 76, 66-74
82. Baltz ML, Caspi D, Evans DJ, Rowe IF, Hind CRK and Pepys MB (1986). Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 66, 691-700
83. Serban D and Rordorf-Adam C (1986). Quantitation of serum amyloid P component by an enzyme-linked immunoassay. J Immunol Methods 90, 159-164
84. Bristow CL and Boackle RJ (1986). Evidence for the binding of human serum amyloid P component to Clq and Fabγ. Mol Immunol 23, 1045-1052
85. Loveless RW, Floyd-O'Sullivan G, Raynes JG, Yuen C-T and Feizi T (1992). Human serum amyloid P is a multispecific adhesive protein whose ligands include 6-phosphorylated mannose and the 3-sulphated saccharides galactose, N-acetyl galactosamine and glucuronic acid. Eur Mol Biol Org J 11, 813-819
86. Swanson SJ, Christner RB and Mortensen RF (1992). Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP). Biochim Biophys Acta 1160, 309-316
87. Hamazaki H (1994). Human serum amyloid P component binds to a specific peptide in the presence of calcium. Biochem Biophys Res Commun 205, 1172-1178
88. Brown MR and Anderson BE (1991). Human serum amyloid P component (SAP) exhibits selective binding of heat or alkali aggregated versus monomeric immunoglobin G. FASEB J 5, A1636
89. Brown MR and Anderson BE (1993). Receptor-ligand interactions between serum amyloid P component and model soluble immune complexes. J Immunol 151, 2087-2095
90. Christner RB and Mortensen RF (1994). Specificity of the binding interaction between human serum amyloid P-component and immobilized human C-reactive protein. J Biol Chem 269, 9760-9766
91. Christner RB and Mortensen RF (1994). Binding of human serum amyloid P-component to phosphocholine. Arch Biochem Biophys 314, 337-343
92. Zahedi K (1996). Characterization of the binding of serum amyloid P to type IV collagen. J Biol Chem 271, 14897-14902
93. Butler JE, Ed. (1991). Immunochemistry of solid-phase immunoassays. (Boca Raton, FL: CRC Press, Inc)
94. de Beer FC, Soutar AK, Baltz ML, Trayner I, Feinstein A and Pepys MB (1982). Low density and very low density lipoproteins are selectively bound by aggregated C-reactive protein. J Exp Med 156, 230-242
95. Dhawan S, Fields RL and Robey FA (1990). A novel peptide from amyloid P component supports cell attachment. Biochem Biophys Res Commun 171, 1284-1290
96. Heegaard NHH and Robey FA (1992). Use of capillary zone electrophoresis to evaluate the binding of anionic carbohydrates to synthetic peptides derived from human serum amyloid P component. Anal Chem 64, 2479-2482
97. Heegaard NHH and Robey FA (1993). Use of capillary zone electrophoresis for the analysis of DNA-binding to a peptide derived from amyloid P component. J Liquid Chromatogr 16, 1923-1939
98. Heegaard NHH, Heegaard PMH, Roepstorff P and Robey FA (1996). Ligand-binding sites in human serum amyloid P component. Eur J Biochem 239, 850-856
99. Pepys MB, de Beer FC, Baltz ML, Holford S and Feinstein A (1982). Binding of C4-binding protein by aggregated serum amyloid P component. Mol Immunol 19, 1395
100. Schwalbe RA, Dahlbäck B and Nelsestuen GL (1990). Independent association of serum amyloid P component, protein S, and complement C4b with complement C4b-binding protein and subsequent association of the complex with membranes. J Biol Chem 265, 21749-21757
101. Schwalbe RA, Dahlbäck B and Nelsestuen GL (1991). Heparin influence on the complex of serum amyloid P component and complement C4b-binding protein. J Biol Chem 266, 12896-12901
102. de Frutos PG, Härdig Y and Dahlbäck B (1995). Serum amyloid P component binding to C4b-binding protein. J Biol Chem 270, 26950-26955
103. Sørensen IJ, Holm Nielsen E, Andersen O, Danielsen B and Svehag S-E (1996). Binding of complement proteins Clq and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand J Immunol 44, 401-407
104. Iwanaga T, Wakasugi S, Inomoto T, Uehira M, Ohnishi S, Nishiguchi S, Araki K, Uno M, Miyazaki J-I, Maeda S, Shimada K and Yamamura K-I (1989). Liver-specific and high-level expression of human serum amyloid P component gene in transgenic mice. Dev Genet 10, 365-371
105. Zhao X, Araki K, Miyazaki J-I and Yamamura K-I (1992). Developmental and liver-specific expression directed by the serum amyloid P component promoter in transgenic mice. J Biochem 111, 736-738
106. Nelson SR, Tennent GA, Sethi D, Gower PE, Ballardie FW, Amatayakul-Chantler S and Pepys MB (1991). Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 200, 191-200
107. Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD and Petrie A (1978). Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 32, 119-124
108. Strachan AF and Johnson PM (1982). Protein SAP (serum amyloid P-component) in Waldenström's macroglobulinaemia, multiple myeloma and rheumatic diseases. J Clin Lab Immunol 8, 153-156
109. Jensson Ó, Bjornsson ÓG, Árnason A, Birgisdóttir B and Pepys MB (1982). Serum amyloid P-component and C-reactive protein in serum of healthy Icelanders and members of an Icelandic family with macroglobulinaemia. Acta Med Scand 211, 341-345
110. Hashimoto S and Migita S (1979). Changes of thirty nine serum protein components following surgical stress. Nippon Ketsucki Gakkai Zasshi 42, 667-677
111. Levo Y, Shalit M and Tur-Kaspa R (1982). Serum amyloid P-component as a marker of liver disease. Am J Gastroenterol 77, 427-430
112. Levo Y, Wollner S and Shalit M (1985). Serum amyloid P-component as a marker of liver involvement in measles infection. Am J Gastroenterol 80, 391-392
113. Hutchinson WL, Noble GE, Hawkins PN and Pepys MB (1994). The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 94, 1390-1396
114. Hawkins PN (1994). Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci 87, 289-295
115. Cathcart ES, Wollheim FA and Cohen AS (1967). Immunoassay of P-component in amyloidotic sera. Proc Soc Exp Biol Med 125, 1123-1125
116. Vigushin DM, Pepys MB and Hawkins PN (1994). Comparison of histology with SAP scintigraphy for evaluation of amyloidosis. In Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ and Young ID (eds). Amyloid and Amyloidosis 1993, pp. 685-687. (Pearl River, New York: Parthenon Publishing)
117. 123I-labeled serum amyloid P component. J Exp Med 167, 903-913
118. Hawkins PN and Pepys MB (1990). A primed state exists in vivo following histological regression of amyloidosis. Clin Exp Immunol 81, 325-328
119. 123I-serum amyloid P component. Lancet 338, 335-339
120. Hawkins PN, Richardson S, MacSweeney JE, King AD, Vigushin DM, Lavender JP and Pepys MB (1993). Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. QJ Med 86, 365-374
121. Hawkins PN, Richardson S, Vigushin DM, David J, Kelsey CR, Gray RES, Hall MA, Woo P, Lavender JP and Pepys MB (1993). Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 36, 842-851
122. Hawkins PN, Vigushin DM, Richardson S, Seymour A and Pepys MB (1994). Evaluation of 100 cases of systemic AL amyloidosis by serum amyloid P component (SAP) scintigraphy. In Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ and Young ID (eds). Amyloid and Amyloidosis 1993, pp. 209-211. (Pearl River, New York: Parthenon Publishing)
123. Hawkins PN, Hall M, Hall R, Penny L, Henderson A, Yacoub M, Mitchell A and Pepys MB (1994). Regression of AL amyloidosis and prolonged survival following cardiac transplantation and chemotherapy. In Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ and Young ID (eds). Amyloid and Amyloidosis 1993, pp. 657-659. (Pearl River, New York: Parthenon Publishing)
124. Tan SY, Irish A, Winearls CG, Brown EA, Gower PE, Clutterbuck EJ, Madhoo S, Lavender JP, Pepys MB and Hawkins PN (1996). Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 50, 282-289
125. Saïle R, Deveaux M, Hachulla E, Descamps J, Duquesnoy B and Marchandise X (1993). Iodine-123-labelled serum amyloid P component scintigraphy in amyloidosis. Eur J Nucl Med 20, 130-137
126. Duquesnoy B, Flipo RM, Deveaux M, Foissac-Gegoux P and Marchandise X (1994). Imaging of dialysis-related amyloid deposits with iodine-123-labeled serum amyloid P component. Rev Rhum (Engl Ed) 61, 33S-37S
127. Hachulla E, Maulin L, Deveaux M, Facon T, Blétry O, Vanhille P, Wechsler B, Godeau P, Levesque H, Hatron PY, Huglo D, Devulder B and Marchandise X (1996). Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Am J Med 101, 77-87
128. Feutrie M-L, Hachulla E, Flipo R-M, Huglo D, Maulin L, Deveaux M, Duquesnoy B, Delcambre B and Marchandise X (1996). Scintigraphy using iodine 123-labeled serum amyloid P component in ten patients with secondary AA type amyloidosis. A descriptive study. Rev Rhum (Engl Ed) 63, 866-873
129. 123I-labelled SAP component scintigraphy and labial salivary gland biopsy. QJ Med 90, 45-50
130. Piirsalu K, McLean R, Zuber R, Bannister K, Penglis S, Bellen J and Bais R (1994). Role of I-123 serum amyloid protein in the detection of familial amyloidosis in Oriental cats. J Small Anim Pract 35, 581-586
131. Burlingame RW, Volzer MA, Harris J and Du Clos TW (1996). The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 156, 4783-4788
132. Levo Y and Wollner S (1985). Effects of serum amyloid P component on human lymphocytes. Int Archs Allergy Appl Immun 77, 322-325
133. Singh PP, Gervais F, Skamene E and Mortensen RF (1986). Serum amyloid P-component-induced enhancement of macrophage listericidal activity. Infect Immun 52, 688-694
134. Sarlo KT and Mortensen RF (1987). Regulation of the antibody response by the acute phase reactant: mouse serum amyloid P-component (SAP). Cell Immunol 106, 273-286
135. Siripont J, Tebo JM and Mortensen RF (1988). Receptor-mediated binding of the acute-phase reactant mouse serum amyloid P-component (SAP) to macrophages. Cell Immunol 117, 239-252
136. Wright SD, Craigmyle LS and Silverstein SC (1983). Fibronectin and serum amyloid P-component stimulate C3b-and C3bi-mediated phagocytosis in cultured human monocytes. J Exp Med 158, 1338-1343
137. Botto M, Hawkins PN, Bickerstaff MCM, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ and Pepys MB (1997). Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Medicine 3, 855-859
138. Hicks PS, Saunero-Nava L, Du Clos TW and Mold C (1992). Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 149, 3689-3694
139. Lachmann PJ, Müller-Eberhard HJ, Kunkel HG and Paronetto F (1962). The localisation of in vivo bound complement in tissue sections. J Exp Med 115, 63-82
140. Eikelenboom P and Stam FC (1984). An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch B Cell Pathol 47, 17-25
141. Eikelenboom P, Hack CE, Rozemuller JM and Stam FC (1989). Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol 56, 259-262
142. Akiyama H, Yamada T, Kawamata T and McGeer PL (1991). Association of amyloid P component with complement proteins in neurologically diseased brain tissue. Brain Res 548, 349-352
143. Isozaki E, Rosoklija G, Neri D and Herbert J (1993). Two different forms of amyloid in polyneuropathy activate the classical complement pathway. Neurology 43, A232
144. Kalaria RN and Kroon SN (1992). Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease. Biochem Biophys Res Commun 186, 461-466
145. Kalaria RN and Perry G (1993). Amyloid P component and other acute-phase proteins associated with cerebellar Aβ-deposits in Alzheimer's disease. Brain Res 631, 151-155
146. Jiang H, Robey FA and Gewurz H (1992). Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human ClqA chain. J Exp Med 175, 1373-1379
147. de Frutos PG and Dahlbäck B (1994). Interaction between serum amyloid P component and C4b-binding protein associated with inhibition of factor I-mediated C4b degradation. J Immunol 152, 2430-2437
148. Hutchcraft C, Gewurz H, Hansen B, Dyck RF and Pepys MB (1981). Agglutination of complement-coated erythrocytes by serum amyloid P component. J Immunol 126, 1217-1219
149. Baltz ML, Holford S, de Beer FC, Whaley K and Pepys MB (1982). The interaction between human serum amyloid P component (SAP) and fixed complement. Ann NY Acad Sci 389, 429
150. Landsmann P, Rosen O, Pontet M, Pras M, Levartowsky D, Shephard EG and Fridkin M (1994). Binding of human serum amyloid P component (hSAP) to human neutrophils. Eur J Biochem 223, 805-811
151. Hind CRK, Collins PM, Baltz ML and Pepys MB (1985). Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Biochem J 225, 107-111
152. Pepys MB, Becker GJ, Dyck RF, McCraw A, Hilgard P, Merton RE and Thomas DP (1980). Studies of human serum amyloid P component (SAP) in relation to coagulation. Clin Chim Acta 105, 83-91
153. Fiedel BA and Ku CSL (1986). Further studies on the modulation of blood coagulation by human serum amyloid P component and its acute phase homologue C-reactive protein. Thromb Haemostas 55, 406-409
154. Meyer K, Smith R and Williams EC (1987). Inhibition of fibrin polymerization by serum amyloid P component and heparin. Thromb Haemostas 57, 345-348
155. Williams EC, Huppert BJ and Asakura S (1992). Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins. J Lab Clin Med 120, 159-167
156. Gates CA and Rees RS (1990). Serum amyloid P component: its role in platelet activation stimulated by sphingomyelinase D purified from the venom of the brown recluse spider (Loxosceles reclusa). Toxicon 28, 1303-1315
157. Schneider H-M and Loos M (1978). Amyloid P component - a special type of collagen? Virchows Arch B Cell Pathol 29, 225-228
158. Dyck RF, Lockwood M, Kershaw M, McHugh N, Duance V, Baltz ML and Pepys MB (1980). Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med 152, 1162-1174
159. Dyck RF, Evans DJ, Lockwood CM, Rees AJ, Turner D and Pepys MB (1980). Amyloid P-component in human glomerular basement membrane: abnormal patterns of immunofluorescent staining in glomerular disease. Lancet ii, 606-609
160. Breathnach SM, Melrose SM, Bhogal B, de Beer FC, Dyck RF, Tennent G, Black MM and Pepys MB (1981). Amyloid P component is located on elastic fibre microfibrils of normal human tissues. Nature 293, 652-654
161. Breathnach SM, Bhogal B, Dyck RF, de Beer FC, Black MM and Pepys MB (1981). Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis. Br J Dermatol 105, 115-124
162. Breathnach SM, Melrose SM, Bhogal B, de Beer FC, Black MM and Pepys MB (1982). Immunohistochemical studies of amyloid P component in disorders of cutaneous elastic tissue. Br J Dermatol 107, 443-452
163. Breathnach SM, Bhogal B, de Beer FC, Melrose SM, Blake MM and Pepys MB (1983). Immunohistochemical studies of amyloid P component and fibronectin in erythropoietic protoporphyria. Br J Dermatol 108, 267-275
164. Breathnach SM, Melrose SM, Bhogal B, de Beer FC, Black MM and Pepys MB (1983). Immunohistochemical studies of amyloid P component distribution in normal human skin. J Invest Dermatol 80, 86-90
165. Orfila C, Rakotoarivony J, Segonds A and Suc JM (1982). Immunofluorescence study of amyloid P-component patterns in human nephropathies. Histochemistry 74, 347-354
166. Clayton SJ and Walker F (1983). The distribution of amyloid P component in normal human cervix. Virchows Arch B Cell Pathol 43, 63-66
167. Kendall CH and Walker F (1984). Amyloid P component in human thyroid. Virchows Arch B Cell Pathol 45, 75-78
168. Khan AM and Walker F (1984). Age related detection of serum amyloid P in the skin. J Pathol 143, 183-186
169. Melvin T, Kim Y and Michael AF (1986). Amyloid P component is not present in the glomerular basement membrane in Alport-type hereditary nephritis. Am J Pathol 125, 460-464
170. Butler MG, D'Ardenne AJ and Scott DL (1988). P component in the synovium in rheumatoid and osteoarthritis. Ann Rheum Dis 47, 463-467
171. Herriot R and Walker F (1989). Age-related deposition of amyloid P component in normal human testis. J Pathol 157, 11-14
172. Li Z-Y, Streeten BW and Yohai N (1989). Amyloid P protein in pseudoexfoliative fibrillopathy. Curr Eye Res 8, 217-227
173. Dahlbäck K, Ljungquist A, Löfberg H, Dahlbäck B, Engvall E and Sakai LY (1990). Fibrillin immunoreactive fibers constitute a unique network in the human dermis: immunohistochemical comparison of the distributions of fibrillin, vitronectin, amyloid P component, and orcein stainable structures in normal skin and elastosis. J Invest Dermatol 94, 284-291
174. Thörneby K, Sakai L and Dahlbäck K (1991). Middermal elastolysis. Report of a case and immunohistochemical studies on the dermal distribution of fibrillin, vitronectin and amyloid P component. Acta Derm Venereol (Stockh) 71, 1-5
175. Al-Mutlaq H, Wheeler J, Robertson H, Watchorn C and Morley AR (1993).
176. Levy SG, McCartney ACE and Moss J (1995). The distribution of fibronectin and P component in Descemet's membrane: an immunoelectron microscopic study. Curr Eye Res 14, 865-870
177. Marshall GE (1995). Human scleral elastic system: an immunoelectron microscopic study. Br J Ophthalmol 79, 57-64
178. Inoue S and Leblond CP (1985). The basement-membrane-like matrix of the mouse EHS tumor: I. Ultrastructure. Am J Anat 174, 373-386
179. Grant DS, Kleinman HK, Leblond CP, Inoue S, Chung AE and Martin GR (1985). The basement-membrane-like matrix of the mouse EHS tumor: II. Immunohistochemical quantitation of six of its components. Am J Anat 174, 387-398
180. Inoue S and Leblond CP (1985). The basement-membrane-like matrix of the mouse EHS tumor: III. Immunodetection of the amyloid P component in basotubules. Am J Anat 174, 399-407
181. Inoue S and Leblond CP (1986). The microfibrils of connective tissue: I. Ultrastructure. Am J Anat 176, 121-138
182. Inoue S, Leblond CP, Grant DS and Rico P (1986). The microfibrils of connective tissue: II. Immunohistochemical detection of the amyloid P component. Am J Anat 176, 139-152
183. Inoue S, Leblond CP, Rico P and Grant D (1989). Association of fibronectin with the microfibrils of connective tissue. Am J Anat 186, 43-54
184. Inoue S, Skinner M, Leblond CP, Shirahama T and Cohen AS (1986). Isolation of the amyloid P component from the Engelbreth-Holm-Swarm (EHS) tumor of the mouse. Biochem Biophys Res Commun 134, 995-999
185. Inoue S (1991). Pentosome - a new connective tissue component - is a subunit of amyloid P. Cell Tissue Res 263, 431-438
186. Pepys MB, Baltz M, Gomer K, Davies AJS and Doenhoff M (1979). Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278, 259-261
187. Westermark P, Shirahama T, Skinner M, Brun A, Cameron R and Cohen AS (1982). Immunohistochemical evidence for the lack of amyloid P component in some intracerebral amyloids. Lab Invest 46, 457-460
188. Rowe IF, Jensson O, Lewis PD, Candy J, Tennent GA and Pepys MB (1984). Immunohistochemical demonstration of amyloid P component in cerebro-vascular amyloidosis. Neuropathol Appl Neurobiol 10, 53-61
189. Kitamoto T, Tateishi J, Hikita K, Nagara H and Takeshita I (1985). A new method to classify amyloid fibril proteins. Acta Neuropathol 67, 272-278
190. Iseki E, Amano N, Matsuishi T, Yokoi S, Arai N and Yagishita S (1988). A case of familial, atypical Alzheimer's disease: immunohistochemical study of amyloid P component. Neuropathol Appl Neurobiol 14, 169-174
191. Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML and Frangione B (1988). Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 58, 454-458
192. Duong T, Pommier EC and Scheibel AB (1989). Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol 78, 429-437
193. Arai H, Sagi N, Noguchi I, Haga S, Ishii T, Makino Y and Kosaka K (1989). An immunohistochemical study of β-protein in Alzheimer-type dementia brains. J Neurol 236, 214-217
194. Kalaria RN, Golde TE, Cohen ML and Younkin SG (1991). Serum amyloid P component in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier. Ann NY Acad Sci 640, 145-148
195. Kalaria RN, Galloway PG and Perry G (1991). Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol Appl Neurobiol 17, 189-201
196. Duong T, Doucette T, Zidenberg NA, Jacobs RW and Scheibel AB (1993). Microtubule-associated proteins tau and amyloid P component in Alzheimer's disease. Brain Res 603, 74-86
197. Perlmutter LS, Myers MA and Barrón E (1994). Vascular basement membrane components and the lesions of Alzheimer's disease: light and electron microscopic analyses. Microsc Res Tech 28, 204-215
198. Kimura M, Arai H, Takahashi T and Iwamoto N (1994). Amyloid-P-component-like immunoreactivity in β/A4-immunoreactive deposits in Alzheimer-type dementia brains. J Neurol 241, 170-174
199. Perlmutter LS, Barrón E, Myers M, Saperia D and Chui HC (1995). Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer's disease lesions. J Comp Neurol 352, 92-105
200. Gallo G, Picken M, Frangione B and Buxbaum J (1988). Nonamyloidotic monoclonal immunoglobulin deposits lack amyloid P component. Mod Pathol 1, 453-456
201. Yang GCH, Nieto R, Strachura I and Gallo GR (1992). Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the Congo red-negative amyloid-like fibrils of fibrillary glomerulopathy. Am J Pathol 141, 409-419
202. Benson MD, Scheinberg MA, Shirahama T, Cathcart ES and Skinner M (1977). Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. J Clin Invest 59, 412-417
203. Baltz ML, Gomer K, Davies AJS, Evans DJ, Klaus GGB and Pepys MB (1980). Differences in the acute phase responses of serum amyloid P component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and resistant mouse strains. Clin Exp Immunol 39, 355-360
204. Zahedi K, Gonnerman WA, de Beer FC, de Beer MC, Steel DM, Sipe JD and Whitehead AS (1991). Major acute-phase reactant synthesis during chronic inflammation in amyloid-susceptible and -resistant mouse strains. Inflammation 15, 1-14
205. Coe JE, Margossian SS, Slayter MS and Sogn JA (1981). Hamster female protein. A new pentraxin structurally and functionally similar to C-reactive protein and amyloid P component. J Exp Med 153, 977-991
206. Coe JE (1982). Female protein of the Syrian hamster: a homolog of C-reactive protein. Ann NY Acad Sci 389, 299
207. Coe JE and Ross MJ (1990). Amyloidosis and female protein in the Syrian hamster. Concurrent regulation by sex hormones. J Exp Med 171, 1257-1267
208. Snel F, Niewold TA, Baltz ML, Hol PR, van Ederen AM, Pepys MB and Gruys E (1989). Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition. Clin Exp Immunol 76, 296-300
209. Woo P, O'Brien J, Robson M and Ansell B (1987). A genetic marker for systemic amyloidosis in juvenile arthritis. Lancet ii, 767-769
210. Harats N, Kluve-Beckerman B, Skinner M, Passo M, Quinn L and Benson MD (1989). Lack of association of a restriction fragment length polymorphism for serum amyloid P gene with reactive amyloidosis. Arthritis Rheum 32, 1325-1327
211. Shohat M, Shohat T, Rotter JI, Schlesinger M, Petersen GM, Pribyl T, Sack G, Schwabe AD and Korenberg JR (1990). Serum amyloid A and P protein genes in familial Mediterranean fever. Genomics 8, 83-89
212. Grateau G, Baudis M and Delpech M (1991). Study of a restriction fragment length polymorphism for serum amyloid P gene in rheumatoid arthritis with amyloidosis. J Rheumatol 18, 994-996
213. Shirahama T, Cohen AS, Rubinow A and Rodgers OG (1980). Ultrastructure of skin biopsies from patients with heredofamilial amyloid polyneuropathy. In Glenner GG, Pinho e Costa P and de Freitas F (eds). Amyloid and Amyloidosis, pp. 132-138. (Amsterdam: Excerpta Medica)
214. Yanagihara M, Kato F, Shikano Y, Fukushima N and Mori S (1985). Intimate structural association of amyloid and elastic fibers in systemic and cutaneous amyloidosis. J Cutan Pathol 12, 110-116
215. Sepp N, Pichler E, Breathnach SM, Fritsch P and Hintner H (1990). Amyloid elastosis: analysis of the role of amyloid P component. J Am Acad Dermatol 22, 27-34
216. Pinteric L and Painter RH (1979). Electron microscopy of serum amyloid protein in the presence of calcium: alternative forms of assembly of pentagonal molecules in two-dimensional lattices. Can J Biochem 57, 727-736
217. Painter RH, de Escallon I, Massey A, Pinteric L and Stern SB (1982). The structure and binding characteristics of serum amyloid protein (9.5S α1-glycoprotein). Ann NY Acad Sci 389, 199-213
218. Hind CRK, Collins PM, Caspi D, Baltz ML and Pepys MB (1984). Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. Lancet ii, 376-378
219. Skogen B and Natvig JB (1981). Degradation of amyloid proteins by different serine proteases. Scand J Immunol 14, 389-396
220. Li JJ and McAdam KPWJ (1984). Human amyloid P component: an elastase inhibitor. Scand J. Immunol 20, 219-226
221. Vachino G, Heck LW, Gelfand JA, Kaplan MM, Burke JF, Berninger RW and McAdam KPWJ (1988). Inhibition of human neutrophil and Pseudomonas elastases by amyloid P-component: a constituent of elastic fibers and amyloid deposits. J Leukoc Biol 44, 529-534
222. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CCF and Pepys MB (1997). Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793
223. Inoue S and Kisilevsky R (1996). A high resolution ultrastructural study of experimental murine AA amyloid. Lab Invest 74, 670-683
224. Hamazaki H (1995). Amyloid P component promotes aggregation of Alzheimer's β-amyloid peptide. Biochem Biophys Res Commun 211, 349-353
225. Webster S and Rogers J (1996). Relative efficacies of amyloid β peptide (Ab) binding proteins in Aβ aggregation. J Neurosci Res 46, 58-66
226. Janciauskiene S, Garcia de Frutos P, Carlemalm E, Dahlbäck B and Eriksson S (1995). Inhibition of Alzheimer β-peptide fibril formation by serum amyloid P component. J Biol Chem 270, 26041-26044
227. 2+-dependent binding of human serum amyloid P component to Alzheimer's β-amyloid peptide. J Biol Chem 270, 10392-10394
228. Kraulis PJ (1991). MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24, 946-950